Literature DB >> 7636970

Mapping of mutations contributing to the temperature sensitivity of the Sabin 1 vaccine strain of poliovirus.

M M Georgescu1, M Tardy-Panit, S Guillot, R Crainic, F Delpeyroux.   

Abstract

The temperature-sensitive and attenuated phenotypes of the Sabin type 1 vaccine strain of poliovirus result from numerous point mutations which occurred in the virulent Mahoney virus parent. One of these mutations is located in a 3D polymerase (3Dpol) codon (U-6203-->C, Tyr-73-->His) and is involved in attenuation in common mice (M. Tardy-Panit, B. Blondel, A. Martin, F. Tekaia, F. Horaud, and F. Delpeyroux, J. Virol. 67:4630-4638, 1993). This mutation also appears to contribute to temperature sensitivity, in association with at least 1 other of the 10 mutations of the 3'-terminal part of the genome including the 3Dpol coding and 3' noncoding regions. To map the other mutation(s), we constructed poliovirus mutants by mutagenesis and recombination of Mahoney and Sabin 1 cDNAs. Characterization of these poliovirus mutants showed that a second mutation in a 3Dpol codon (C-7071-->U, Thr-362-->Ile) contributes to temperature sensitivity. A mutation in the 3' noncoding region of the genome (A-7441-->G), alone or linked to another mutation (U-7410-->C), also appeared to be involved in this phenotype. The temperature-sensitive effect associated with the 3'-terminal part of the Sabin 1 genome results from the cumulative and/or synergistic effects of at least three genetic determinants, i.e., the His-73 and Ile-362 codons of 3Dpol and nucleotide G-7441. Sequence analysis of strains isolated from patients with vaccine-associated paralytic poliomyelitis showed that these genetic determinants are selected against in vivo, although the Ile-362 codon appeared to be more stable than either the His-73 codon or G-7441. These genetic determinants may contribute to the safety of Sabin 1 in vaccines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636970      PMCID: PMC189363     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  A functional ribonucleoprotein complex forms around the 5' end of poliovirus RNA.

Authors:  R Andino; G E Rieckhof; D Baltimore
Journal:  Cell       Date:  1990-10-19       Impact factor: 41.582

2.  Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees.

Authors:  A J Macadam; C Arnold; J Howlett; A John; S Marsden; F Taffs; P Reeve; N Hamada; K Wareham; J Almond
Journal:  Virology       Date:  1989-10       Impact factor: 3.616

3.  A poliovirus temperature-sensitive RNA synthesis mutant located in a noncoding region of the genome.

Authors:  P Sarnow; H D Bernstein; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

4.  Genetic analysis of the attenuation phenotype of poliovirus type 1.

Authors:  T Omata; M Kohara; S Kuge; T Komatsu; S Abe; B L Semler; A Kameda; H Itoh; M Arita; E Wimmer
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

5.  Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants.

Authors:  H Toyoda; M Kohara; Y Kataoka; T Suganuma; T Omata; N Imura; A Nomoto
Journal:  J Mol Biol       Date:  1984-04-25       Impact factor: 5.469

6.  Molecular pathogenesis of neural lesions induced by poliovirus type 1.

Authors:  T Couderc; C Christodoulou; H Kopecka; S Marsden; L F Taffs; R Crainic; F Horaud
Journal:  J Gen Virol       Date:  1989-11       Impact factor: 3.891

7.  High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; F Delpeyroux; M Tardy-Panit; J Balanant; M Combiescu; A A Combiescu; S Guillot; R Crainic
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model.

Authors:  A Martin; D Benichou; T Couderc; J M Hogle; C Wychowski; S Van der Werf; M Girard
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

9.  A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice.

Authors:  M Tardy-Panit; B Blondel; A Martin; F Tekaia; F Horaud; F Delpeyroux
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  Clustered charged-to-alanine mutagenesis of poliovirus RNA-dependent RNA polymerase yields multiple temperature-sensitive mutants defective in RNA synthesis.

Authors:  S E Diamond; K Kirkegaard
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

View more
  11 in total

1.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

2.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; J Balanant; A Macadam; D Otelea; M Combiescu; A A Combiescu; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Impact of exogenous sequences on the characteristics of an epidemic type 2 recombinant vaccine-derived poliovirus.

Authors:  Franck B Riquet; Claire Blanchard; Sophie Jegouic; Jean Balanant; Sophie Guillot; Marie-Anne Vibet; Mala Rakoto-Andrianarivelo; Francis Delpeyroux
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

5.  Mechanisms controlling virulence thresholds of mixed viral populations.

Authors:  Karen Z Lancaster; Julie K Pfeiffer
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

6.  Cell-dependent role for the poliovirus 3' noncoding region in positive-strand RNA synthesis.

Authors:  David M Brown; Steven E Kauder; Christopher T Cornell; Gwendolyn M Jang; Vincent R Racaniello; Bert L Semler
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

7.  Growth kinetic analysis of bi-recombinant poliovirus vaccine strains.

Authors:  Vaia Pliaka; Evaggelos Dedepsidis; Zaharoula Kyriakopoulou; Georgia Papadi; Dimitris Tsakogiannis; Anastassia Pratti; Stamatina Levidiotou-Stefanou; Panayotis Markoulatos
Journal:  Virus Genes       Date:  2010-01-21       Impact factor: 2.332

8.  Vaccine-derived mutation in motif D of poliovirus RNA-dependent RNA polymerase lowers nucleotide incorporation fidelity.

Authors:  Xinran Liu; Xiaorong Yang; Cheri A Lee; Ibrahim M Moustafa; Eric D Smidansky; David Lum; Jamie J Arnold; Craig E Cameron; David D Boehr
Journal:  J Biol Chem       Date:  2013-09-30       Impact factor: 5.157

9.  Transmission of human enterovirus 85 recombinants containing new unknown serotype HEV-B donor sequences in Xinjiang Uighur autonomous region, China.

Authors:  Qiang Sun; Yong Zhang; Shuangli Zhu; Huifang Tian; Guohong Huang; Hui Cui; Xiaolei Li; Dongmei Yan; Zhen Zhu; Jing Li; Peng Zheng; Huafang Jiang; Bo Zhang; Xiaojuan Tan; Hui Zhu; Hongqiu An; Wenbo Xu
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

10.  Recombination between polioviruses and co-circulating Coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses.

Authors:  Sophie Jegouic; Marie-Line Joffret; Claire Blanchard; Franck B Riquet; Céline Perret; Isabelle Pelletier; Florence Colbere-Garapin; Mala Rakoto-Andrianarivelo; Francis Delpeyroux
Journal:  PLoS Pathog       Date:  2009-05-01       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.